RIPK3 and cancer: Natural compounds such as Erigeron breviscapus have been shown to induce necroptosis in cancer cells by activating the RIPK1–RIPK3–MLKL signaling axis, highlighting their potential as necroptosis‐based therapeutic agents [62].